Despite the global increase in resistant pathogens, hardly any new antibiotics have come onto the market in recent decades. Marc Gitzinger, CEO of the Basel-based start-up BioVersys, calls for new reimbursement models for antibiotics.

Curious to read on?
Below you will find the link to the full article published by Handelskammer beider Basel.

Antibiotika sind Opfer ihres eigenen Erfolges – Handelskammer beider Basel (hkbb.ch)